The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Authors
Keywords
Acromegaly, Somatostatin analogue, Octreotide, Lanreotide, Pasireotide, Tumor volume
Journal
Pituitary
Volume 19, Issue 2, Pages 210-221
Publisher
Springer Nature
Online
2015-08-19
DOI
10.1007/s11102-015-0677-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Treatment with Pegvisomant as Monotherapy in Patients with Acromegaly: Experience from Acrostudy
- (2015) Pamela Freda et al. Endocrine Practice
- Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long?
- (2014) Jubbin J. Jacob et al. CLINICAL ENDOCRINOLOGY
- Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
- (2014) A. Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
- (2014) Mônica R Gadelha et al. Lancet Diabetes & Endocrinology
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update
- (2013) Laurence Katznelson et al. Endocrine Practice
- Somatostatin receptors: From signaling to clinical practice
- (2013) Marily Theodoropoulou et al. FRONTIERS IN NEUROENDOCRINOLOGY
- A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy
- (2013) Anand K. Annamalai et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Endoscopic vs Microsurgical Transsphenoidal Surgery for Acromegaly: Outcomes in a Concurrent Series of Patients Using Modern Criteria For Remission
- (2013) Robert M. Starke et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
- (2013) Philippe J. Caron et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
- (2013) Stephan Petersenn et al. Pituitary
- Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
- (2013) M. Boscaro et al. Pituitary
- Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis
- (2013) Francisco Pita-Gutierrez et al. PLoS One
- Somatostatin analogs as a first-line treatment in acromegaly
- (2013) Ludovica F.S. Grasso et al. Current Opinion in Endocrinology Diabetes and Obesity
- Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
- (2012) A. J. van der Lely et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
- (2012) Annamaria Colao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to Somatostatin Analogs in Acromegaly
- (2011) Annamaria Colao et al. ENDOCRINE REVIEWS
- The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells
- (2010) V. Cerovac et al. CANCER RESEARCH
- Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
- (2010) S. Petersenn et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- ZAC1 target genes and pituitary tumorigenesis
- (2010) Marily Theodoropoulou et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Pasireotide and Octreotide Stimulate Distinct Patterns of sst2ASomatostatin Receptor Phosphorylation
- (2010) Florian Pöll et al. MOLECULAR ENDOCRINOLOGY
- VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway
- (2010) Karine Villaume et al. NEUROENDOCRINOLOGY
- Transcriptional Activation of the Mixed Lineage Leukemia-p27Kip1 Pathway by a Somatostatin Analogue
- (2009) K. Horiguchi et al. CLINICAL CANCER RESEARCH
- Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
- (2009) SJCMM Neggers et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly
- (2009) Marily Theodoropoulou et al. INTERNATIONAL JOURNAL OF CANCER
- Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study
- (2009) Annamaria Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Guidelines for Acromegaly Management: An Update
- (2009) S. Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways
- (2009) Renzo Cescato et al. MOLECULAR ENDOCRINOLOGY
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
- (2009) Gherardo Mazziotti et al. Pituitary
- Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment
- (2009) Ana Paula M. Casarini et al. Pituitary
- Octreotide LARvs.surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study
- (2008) Annamaria Colao et al. CLINICAL ENDOCRINOLOGY
- Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
- (2008) Annamaria Colao et al. CLINICAL ENDOCRINOLOGY
- Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
- (2008) Giselle F Taboada et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Growth Hormone-Secreting Tumor Shrinkage after 3 Months of Octreotide-Long-Acting Release Therapy Predicts the Response at 12 Months
- (2008) Annamaria Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure Short-Term Postoperative Rates: A Prospective, Randomized Trial
- (2008) Sven M. Carlsen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial
- (2008) M. Boscaro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Antitumor effects of somatostatin
- (2008) Stéphane Pyronnet et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment
- (2008) Masamichi Kurosaki et al. NEUROLOGICAL RESEARCH
- Acromegaly
- (2008) Philippe Chanson et al. Orphanet Journal of Rare Diseases
- Somatostatin agonists for treatment of acromegaly
- (2007) Anat Ben-Shlomo et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Pasireotide (SOM230): Development, mechanism of action and potential applications
- (2007) Herbert A. Schmid MOLECULAR AND CELLULAR ENDOCRINOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now